Stroke Recurrence And Mortality With Recombinant Tissue Kallikrein Protein In The Remedy1 Phase 2 Trial

Randomized, Double-blind, Placebo-controlled, Adaptive Design Study To Evaluate Dm199 For The Treatment Of Acute Ischemic Stroke (ReMEDy2 Trial)